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Abstract  
 
We present a laboratory-based prognostic calculator (designated CRO score) to risk stratify 
treatment-free survival in early stage (Rai 0) chronic lymphocytic leukemia developed using a 
training-validation model in a series of 1,879 cases from Italy, the United Kingdom and the 
United States.  By means of regression analysis, we identified five prognostic variables with 
weighting as follows: deletion of the short arm of chromosome 17 and unmutated 
immunoglobulin heavy chain gene status, 2 points; deletion of the long arm of chromosome 11, 
trisomy of chromosome 12, and white blood cell count>32.0x103/microliter, 1 point.  Low, 
intermediate and high-risk categories were established by recursive partitioning in a training 
cohort of 478 cases, and then validated in four independent cohorts of 144/395/540/322 cases, as 
well as in the composite validation cohort.  Concordance indices were 0.75 in the training cohort 
and ranged from 0.63 to 0.74 in the four validation cohorts (0.69 in the composite validation 
cohort).  These findings advocate potential application of our novel prognostic calculator to 
better stratify early-stage chronic lymphocytic leukemia, and aid case selection in risk-adapted 
treatment for early disease.  Furthermore, they support immunocytogenetic analysis in Rai 0 
chronic lymphocytic leukemia being performed at the time of diagnosis to aid prognosis and 
treatment, particularly in today’s chemo-free era.  
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Introduction 
 
Clinical staging using the Binet and Rai classification systems provide a simple and inexpensive 
approach to assess prognosis in chronic lymphocytic leukemia (CLL) (1, 2).  However, most 
patients today are diagnosed in early stages of the disease (Binet A or Rai 0), when these 
prognosticators fail to provide adequate risk stratification (3).  Although similarly classified as 
early-stage CLL, Binet A and Rai 0 patients demonstrate heterogeneous clinical courses ranging 
from normal life expectancy in the absence of any treatment to unexpectedly short progression-
free intervals rapidly requiring clinical intervention (4). 
 
To overcome the inherent weakness of clinical staging systems, other parameters have been 
sought and proposed by several studies as reliable prognosticators in CLL, including 
immunocytogenetic and molecular markers such as deletions of the short arm of chromosome 17 
(del17p) and mutations of the TP53 gene, deletions of the long arm of chromosome 11 (del11q), 
and trisomy of chromosome 12 (tris12), the immunoglobulin heavy chain (IGHV) gene 
mutational status as well as biochemical parameters such as beta-2-microglobulin (B2M) and 
thymidine kinase (TK) and cell surface receptors such as the integrin CD49d (5-10).   
 
Novel prognostic indices and model systems have been developed to integrate these markers in 
comprehensive scoring systems, such as the CLL International Prognostic Index (CLL-IPI), the 
German CLL Study Group (GCLLSG) index, and the MDACC score (11-14).  Although 
validations in the setting of early-stage CLL and/or treatment-free-survival (TFS) prediction 
have been undertaken, these indices were originally generated to predict overall survival 
operating across all stages of disease (11, 13, 15, 16).   
 
Here we present a novel laboratory-based prognostic index specifically developed to predict TFS 
in Rai 0 CLL, thus allowing clinicians and researchers to uniformly and more accurately identify 
cases with higher risk for needing early treatment.   
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Methods 
 
We applied a training-validation strategy using 1,879 cases of phenotypically confirmed Rai 0 
CLL (17) collected in the context of an international effort from Italy, the United Kingdom and 
the United States (Figure 1).  The training cohort included 478 Rai 0 cases identified from a 
consecutive series of Italian multicenter patients (1,201 cases) referred to a single center 
(Clinical and Experimental Onco-Hematology Unit of the Centro Riferimento Oncologico in 
Aviano, IT) for immunocytogenetic analyses between 2006 and 2017. Four independent Rai 0 
cohorts were used for external validation: three ‘real world’ cohorts from single centers—i) 
Gemelli Hospital in Rome, IT (144 cases, Gemelli cohort), ii) Cardiff University Hospital in 
Wales, UK (395 cases, Cardiff cohort), iii) Mayo Clinic in Rochester, MN (540 cases, Mayo 
cohort)—and one investigational cohort from the multicenter O-CLL1-GISL Italian prospective 
observational study (O-CLL cohort; clinicaltrial.gov identifier: NCT00917540; 322 cases) 
(Figure 1).  Cases of monoclonal B lymphocytosis were excluded, and the TFS was defined as 
time from diagnosis to treatment, according to the revised 2018 iwCLL guidelines (18). Patient 
information was obtained from the participating centers in accordance with the Declaration of 
Helsinki and local Ethics Committee approvals (Approvals n. IRB-05-2010, LREC #02/4806, 
IRB-12-000969 and NCT00917540). 
 
Deletions at chromosomes 13q14 (del13q), 11q23 (del11q), 17p13 (del17p), and trisomy 12 
(tris12), and IGHV gene status were determined at the different participating centers, as reported 
previously (5, 19). Cytogenetic thresholds were set at 5% for del13q, del11q, and tris12 and 10% 
for del17p, and cases were categorized according to the hierarchical model proposed by Dohner 
et al (7).  The positive FISH threshold of 10% for del17p was selected in accordance with ERIC 
recommendations and previous clinical studies (20-22). IGHV status was considered unmutated 
(UM) at ≥98% (6), and CD49d positivity, only determined in the training cohort, was set at 
>30%, as reported previously (19).Investigation of mutations for TP53 (exons 2–11), and 
NOTCH1 (exon 34), determined in 304/478 cases in the training cohort,was performed by a next-
generation sequencing (NGS) approach, as previously reported(5, 23-26).  In the case of TP53 
mutation, cases were defined as TP53 mutated if the variant allele frequency was >10%, 
according to ERIC recommendations (27). 
 
The Cox proportional hazards regression model was chosen to assess the independent effect of 
covariables on TFS, with a stepwise procedure for selecting significant variables.  All 
covariables, aside from FISH categories (7), were treated as dichotomous and evaluated at 
diagnosis. Independent variables were internally validated using bootstrapping procedures and 
weighted based on the proportion of their normalized hazard ratios (HRs) rounded to the nearest 
whole integer (Table 1). Risk-categories were determined by recursive partitioning 
(Supplementary Figure 2), and Kaplan-Meier analyses were used to generate survival curves.  
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In the training cohort, five cases died without treatment and were censored at the date of death. A 
sensitivity analysis for competitive risk, conducted on the training cohort according to the Fine-
Gray model (28), reported no substantial modification in risk magnitude (not shown).   
 
The concordance index (C-index) was used to compare our model with the CLL-IPI (11) in 
418/478 (training cohort), 144/144 (Gemelli cohort), 395/395 (Cardiff cohort), 540/540 (Mayo 
cohort), 239/322 (O-CLL cohort), and 1,318/1,401 (composite validation cohort) cases with 
available B2M data.  In all cases, the statistical significance between C-indices was evaluated by 
applying the Student’s t-test and internally validated by applying a bootstrapping procedure.  The 
Akaike information criterion (AIC) was also employed as an estimator of the relative quality of 
the model proposed in this study in comparison to the CLL-IPI as TFS predictors.  When 
applicable, values were considered statistically significant at a p-value <0.05.  Statistical 
calculations were made using MedCalc or the open source R package (http://www.r-project.org/) 
statistics software.   
  
7 
 
Results 
 
Identification of the training cohort and construction of a scoring system 
The TFS curves of a consecutive series of 1,201 cases from a single center, split according to Rai 
staging are reported in Figure 2A.  As expected, the median (95% confidence interval [CI]) TFS 
of the 478 Rai 0 cases was significantly longer at 124 months (m) (104-183m) compared to that 
of Rai I-IV cases, with a median (95% CI) follow up of 62m (57-68m 95% CI).  The baseline 
characteristics of this Rai 0 cohort are summarized in Supplementary Table 1.  When Dohner’s 
hierarchical model (7) was applied to this Rai 0 cohort, cases bearing either del17p, del11q or 
tris12 experienced the shortest TFS, without differences among these three cytogenetic 
categories, while similarly longer TFS intervals were observed for del13q cases and cases 
lacking the four major chromosomal abnormalities (Figure 2B).  
 
Therefore, the presence of these three chromosomal aberrations were included, along with white 
blood cell (WBC) counts, IGHV gene status, CD49d expression, gender and age in a univariate 
analysis.  For the purposes of the present study, WBC counts were dichotomized according to the 
cutoff of >32 x 103 cells/μl (32K), as established by a maximally selected log rank analysis 
carried out in the training cohort (Supplementary Figure 1).  In patients with WBC counts≤32K 
and >32K, median (95% CI, x103 cell/μL) counts were 15.3 (15.0-16.8) versus 54.7 (49.8-58.0), 
respectively without clustering around the threshold value (Supplementary Figure 2). 
 
As shown in Table 1, apart from age and gender, all of the tested variables associated with a 
shorter TFS, and five of them (del17p, del11q, tris12, WBC and IGHV gene status) emerged as 
independent predictors of short TFS by multivariate analysis.  
 
To construct a scoring system (hereafter designated as the CRO score) using these five 
independent predictors, a point value of 1 or 2 was assigned to variables according to their 
respective normalized hazard ratios as follows: i) 2 points to del17p, and UM IGHV; ii) 1 point 
to del11q, tris12, and WBC count>32K (Table 1).  Then, three risk groups, based on point cut-
offs of 0 (low risk, 218 cases), 1-2 (intermediate risk, 159 cases), and 3-5 (high risk, 101 cases) 
were established by recursive partitioning analysis (Supplementary Figure 3).  The median TFS 
(95% CI) was 216 m (216-216 m), 104 m (93-140 m) and 58 m (44-68 m) (p<0.0001) for the 
low, intermediate, and high-risk groups, respectively, with a C-index of 0.75 (Figure 2C).  A 
comparison with the CLL-IPI, possible in 418/478 cases with available B2M data, indicated a C-
index of 0.76 for the CRO score compared to 0.69 when patient risk groups were split according 
to the CLL-IPI (p<0.0001) (Supplementary Figure 4A).    
 
External validation of the CRO score 
The CRO score was then validated in four independent cohorts of Rai 0 CLL with baseline 
patient characteristics reported in Supplemental Table 1.  These cohorts demonstrated similar 
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TFS survival curves when compared to each other and the training series (Supplementary Figure 
5).  Results, summarized in Figure 3, were as follows:  
 
i) The 144 cases of the Gemelli cohort (Figure 3A) had a median (95% CI) follow up of 91 m 
(83-103 m). Overall, median (95% CI) TFS was 86m (80-94m) (Supplementary Figure 5), while 
median (95% CI) TFS for the low (96 cases), intermediate (36 cases) and high-risk (12 cases) 
groups was 239 m (239-239 m), 98 m (92-132 m) and 85 m (60-109 m) respectively (p=0.002 
between low and intermediate groups, p=0.09 between intermediate and high groups).  In this 
cohort, the C-indices were 0.64 and 0.61 for the CRO score and the CLL-IPI, respectively 
(p<0.0001) (Supplementary Figure 4B).   
 
ii) The Cardiff cohort (395 cases) had a median (95% CI) follow up of 94 m (83-104 m). Median 
(95% CI) TFS was 74 m (67-81 m) overall (Supplementary Figure 5), and non-reached (NR), 
111 m (97-146 m) and 70 m (29-114 m) for the low (206 cases), intermediate (136 cases) and 
high-risk (53 cases) groups, respectively (p<0.001 between low and intermediate groups, 
p=0.009 between intermediate and high groups) (Figure 3B); C-index was 0.63 for both the CRO 
score and the CLL-IPI (p=ns) (Supplementary Figure 4C). 
 
iii) The Mayo cohort (540 cases) had a median (95% CI) follow up of 77 m (68-88 m).  Median 
(95% CI) TFS was 127 m (96 m-NR) overall (Supplementary Figure 5), and NR, 76 m (64 m-
NR) and 36 m (31-59 m) for the low (278 cases), intermediate (168 cases) and high-risk (94 
cases) groups, respectively (p<0.0001) (Figure 3C); C-indices were 0.72 and 0.68 for the CRO 
score and the CLL-IPI, respectively (p<0.0001) (Supplementary Figure 4D). 
 
iv) The multicenter O-CLL cohort (322 cases) had a median (95% CI) follow up of 89 m (85-95 
m), while median (95% CI) TFS was NR overall (Supplementary Figure 5), and NR, 96 m (83-
110 m) and 48 m (39-67 m) for the low (189 cases), intermediate (84 cases) and high-risk (49 
cases) groups, respectively (p<0.001 between low and intermediate groups, p=0.003 between 
intermediate and high groups; C-index 0.74) (Figure 3D).  In the 239 cases with available B2M 
data, the C-indices were 0.71 and 0.70 for the CRO score and the CLL-IPI, respectively 
(p<0.001) (Supplementary Figure 4E). 
 
The composite TFS curve included 1,401 Rai 0 cases by combining cases from the four 
validation cohorts.  Median (95% CI) TFS was 175 m (143-201 m) overall and NR, 106 m (96-
134 m) and 45 m (39-60 m) for the low, intermediate and high-risk groups respectively 
(p<0.0001; C-index 0.69) (Figure 5E).  In the 1,318 cases with available B2M data, the C-indices 
were 0.68 for the CRO score and 0.66 for the CLL-IPI (p<0.0001; Supplemental Figure 6).  In 
this context, AIC was 4,881 for the CRO score vs. 4,912 for the CLL-IPI, in keeping with a 
relative better quality of the former as a TFS predictor.   
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Sub-analyses of the CRO score high-risk group  
By combining the training and four validation cohorts, 309/1,879 cases (16%) were identified as 
having relatively higher risk of early progression and treatment according to the CRO score 
(scores 3, 4 or 5).  In this subset, the vast majority of cases had a CRO score of 3 (223 cases, 
72%) or 4 (72 cases, 23%); however, a small minority of patients (14 cases, 4.5%) had a CRO 
score of 5, i.e. presented with a WBC count >32K in the context of disease bearing both del17p 
and an UM IGHV gene status (Table S2).  Although the median TFS of cases with CRO scores 3 
and 4 were similar, a significantly shortened median TFS was demonstrated in patients classified 
as high-risk with a CRO score of 5 (27.6 m, 95% CI 14.4-28.8; p = 0.01) (Table S2 and 
Supplementary Figure 7).  
 
Application of the CRO score in Rai I patients 
To assess the generalizability of the CRO score in patients beyond Rai 0 disease, we applied our 
scoring system to a consecutive series of Italian multicenter patients with Rai I CLL (375 cases) 
referred to our center for immunocytogenic analyses between 2006 and 2017.  Our prognostic 
calculator demonstrated excellent predictive performance in this cohort (c-index 0.67) with a 
median (95% CI) TFS of 37 m (47-57 m) (Supplementary Figure 8). 
 
CRO score variables and TP53 and NOTCH1 mutations 
Data of TP53 and NOTCH1 mutations were available in 304/478 cases from the training cohort.  
Therefore, a multivariable analysis was performed in these cases by including the same variables 
(WBC count, del11q, tris12, IGHV gene status, CD49d, age and gender), adding NOTCH1 and 
TP53 mutations and re-classifying del17p and/or TP53 mutated cases as TP53 disrupted (5, 29-
31).  As shown in Supplemental Table 3, the CRO score variables WBC count, del11q, tris12, 
and IGHV gene status maintained the ability to independently predict short TFS along with TP53 
disruption, in a model that included TP53 and NOTCH1 gene mutations.  
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Discussion 
 
The clinical staging systems for CLL, described by Rai and Binet approximately 40 years ago, 
are still used today in clinical practice to inform prognosis and guide treatment decisions (1, 2).  
However, their predictive powers are limited (3).  For example, Pflug et al reported C-indices of 
0.56 and 0.58 for Rai and Binet systems, respectively, when applied to a cohort of 1,948 patients 
(13).  Novel model scoring systems developed in recent years have significantly improved the 
accuracy of prognostication by incorporating new biomarkers and hold the potential for the 
development of more individualized treatment strategies (11-14, 26) especially in the age of 
increasing sophistication of novel agents alone or in combination.  In this regard, the CLL-IPI 
was developed as an integrative tool to evaluate overall survival for all clinical stages of disease, 
and although it demonstrated consistency in subgroup analyses circumscribed to early-stage 
disease (15, 32), it was not developed specifically to predict TFS.   
 
To our knowledge, this study represents one of the largest attempts to integrate novel biomarkers 
with traditional clinical factors, with the specific aim of predicting TFS in the setting of Rai 0 
CLL.  Given the multiplicity of new biomarkers our goals were: i) to determine which ones 
individually influence TFS; and ii) to develop a scoring system to stratify risk in patients 
traditionally thought to harbor indolent disease.   
 
Our training cohort was selected from a consecutive series of 1,201 CLL cases referred to a 
single center for immunocytogenetic analyses between 2006 and 2017.  With respect to TFS, this 
cohort was stratified into independent risk groups using Rai staging; however, a satisfying 
further sub-stratification of Rai 0 cases was not demonstrated using the canonical Dohner’s 
hierarchical classification alone (7).  This observation provided the stimulus to investigate the 
potential prognostic significance of additional biomarkers in early-stage disease.  One of our 
main strategies was to integrate known prognostic markers that are commonly used in clinical 
practice today to increase the accessibility and cost-effectiveness of the risk tool. 
 
Our results demonstrate that the CRO score is a powerful tool for guiding treatment prediction in 
patients with Rai 0 CLL.  Notably, a subset analysis of the so-called high-risk category according 
to the CRO score (i.e. scores 3-5), revealed that a very small subset of cases (14 cases) in a 
composite cohort of 1,879 training and validation cases, characterized by high WBC counts in 
the setting of del17p and UM IGHV gene status (i.e. CRO score 5), progressed within two years, 
significantly more rapidly than the other so-called high-risk cases with CRO scores of 3 or 4. 
Conversely, in low-risk patients, the CRO score predicted TFS at 10 years ~85% arguing for its 
expanded utility in allowing clinicians to confidently provide reassurance of disease quiescence 
to such patients.  Furthermore, in comparison to the CLL-IPI (11), our model demonstrated 
superior performance in the training cohort and in 3 out of the 4 validation cohorts, lending 
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credence to its role in the current compendium of comprehensive risk tools in the setting of Rai 0 
CLL. 
 
We observed significant heterogeneity in patient characteristics among the five cohorts included 
in our study (Table S1).  For example, 64% of patients in the Gemelli cohort were aged ≥ 65y 
compared to 30% in the O-CLL cohort and only 1 patient in the O-CLL had a B2M >3.5 mg, 
compared to 23% of the patients in the Cardiff cohort.  We attribute these differences to the 
heterogeneity of clinical settings from which each cohort was derived as has been observed in 
previous studies comparing ‘real world’ versus observational study patients, single versus 
multicenter registries, and cases from community versus tertiary/referral centers (33-35).  In 
contrast to the results in these studies, which show inconsistent performance of several 
prognostic indexes across dissimilar cohorts, our scoring system retained powerful predictive 
capacity throughout, showcasing its generalizability and strength as a clinically useful decision-
making tool. 
 
In the training, composite and two out of four validation cohorts, the proposed prognostic score 
approached or exceeded C-index values of 0.7, a threshold necessary to confer utility at the 
individual patient level (36).  In this regard, however, a more precise evaluation of the individual 
predictive potential may require the application of complex statistical methods, as recently 
proposed (37, 38). 
 
This study raises questions regarding the appropriate timing of immunocytogenetic analysis in 
early-stage disease, which today is often postponed until the time of disease progression and first 
treatment.  We appreciate the cost-effectiveness of a watch-and-wait approach particularly since 
studies investigating the early use of chlorambucil and fludarabine monotherapy as well as FCR 
regimens (fludarabine/cyclophosphamide + rituximab) have failed to demonstrate improved 
outcomes in CLL patients (18, 39, 40).  However, the role of the novel inhibitors in this setting 
remains to be elucidated (41), and the results of this study supports the notion that early testing 
can aid risk-adapted treatment strategies and early intervention particularly in the modern 
chemo-free era.  In this regard, the CLL12 trial, a phase III clinical study currently underway in 
Germany, is evaluating the efficacy and safety of ibrutinib compared to a watch-and-wait 
approach in Binet A CLL using a similar comprehensive scoring system to identify high-risk 
patients (36).  Another randomized phase II study currently underway at the Mayo Clinic is 
comparing the efficacy of the BTK inhibitor acalabrutinib alone and in combination with the 
anti-CD20 obinutuzumab in treating patients with early-stage CLL who are classified high or 
very high-risk according to the CLL-IPI (Sameer Parikh et al., 2018, NCT03516617).  Further 
clinical studies are needed to aid identification of progressive cases of early-stage disease who 
may benefit from risk-adapted treatment approaches.  An important caveat to the approach of up-
front testing is that cytogenetic and TP53 mutational analysis must be repeated at the time of 
disease progression and/or treatment particularly in previously so-called “TP53 non-disrupted” 
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cases to identify those that have undergone clonal evolution which could affect treatment 
decisions. 
 
We realize several limitations of our study.  As an example, we did not include TP53 gene 
mutation, an important adverse prognostic factor that, together with del17p, recapitulates the so-
called “TP53 disrupted” cases (31).  While the established cut-off of 10% for del17p has little 
biological substantiation, its selection helps mitigate false positive rates.  In the era of next 
generation sequencing however, TP53 mutational analysis is admittedly preferred.  Despite the 
exclusion of TP53 mutational analysis in this study, we were able to achieve superior prognostic 
power with respect to the CLL-IPI, in keeping with the notion that the majority of del17p cases 
also bear TP53 mutations in the undeleted allele (29, 30), and that the clinical impact of 
subclonal TP53 mutations (31), especially if detected alone in early-stage disease, remains to be 
completely understood.  Furthermore, subgroup analysis of 304 cases from the training cohort 
demonstrated the preservation of CRO score variables even in the presence of TP53 and 
NOTCH1 gene mutations (Supplemental Table 3).  We also excluded from our analysis other 
gene mutations usually associated with disease progression, namely BIRC3 and SF3B1 (42-45) 
although, notably, these mutations have mainly failed to operate as independent predictors when 
tested in large cohorts (5, 46).  Similarly, we did not include in our panel of biomarkers the 
evaluation of serum thymidine kinase levels, a test with independent clinical relevance as a 
predictor of overall survival, according to some studies (13).  This assay, however, is of limited 
application in CLL and is currently not routinely employed in many U.S. and European clinical 
laboratories.  
 
We have not overlooked the uniqueness of including WBC count as a prognostic biomarker in 
this study.  More commonly, B-cell lymphocyte count is employed in the diagnosis and response 
to therapy in CLL (18).  However we demonstrated here, commensurate with previously 
published studies (47), that WBC count may deserve consideration as a clinically useful 
surrogate marker of disease burden particularly in the setting of untreated disease where, 
alongside del17p and unmutated IGHV gene status, it appears to demonstrate prognostic 
significance.  This observation is consistent with previous data demonstrating WBC count, along 
with IGHV, as independent predictors of TFS in Binet A CLL (48). 
 
Finally, CD49d, a well-proven independent prognosticator in CLL (19, 49) including in cases of 
early-stage disease (50), failed, perhaps surprisingly, to emerge in multivariable analysis as an 
independent factor in our Rai 0 training cohort.  We hypothesize that the dropout of CD49d in 
multivariate analysis was due to the close relationship between CD49d and tris12 (51), the latter 
maintained in the final multivariable model; this idea is supported by bivariate analysis of these 
two variables wherein CD49d lost significance (data not shown).  
 
13 
 
In conclusion, we present herein a novel laboratory-based scoring system for Rai 0 CLL to aid 
clinical decision making in cases of early-stage disease.  These findings advocate for the role of 
immunocytogenetic analysis in Rai 0 CLL at the time of diagnosis to aid prognosis, particularly 
in today’s chemo-free era where early intervention is acquiring momentum in the investigative 
setting.  Further investigation is needed to definitively validate its utility in risk-adapted 
treatment. 
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Table 1.  Univariable and reduced multivariable analysis of 6 factors used to generate our risk 
calculator.    
Factor 
Univariable Analysis Reduced Multivariable Analysis 
P HR 95% CI P HR 95% CI Weight 
WBC>32K cells/μL <0.0001 2.96 2.10 to 4.16 <0.0001 2.39 1.69 to 3.38 1 
FISH category 
       
del17p <0.0001 4.38 2.46 to 7.80 0.0002 3.03 1.69 to 5.44 2 
del11q <0.0001 4.02 2.45 to 6.19 0.0049 2.13 1.26 to 3.62 1 
tri12 <0.0001 2.85 1.84 to 4.42 0.025 1.7 1.07 to 2.71 1 
UM IGHV <0.0001 4.08 2.86 to 5.80 <0.0001 2.91 1.97 to 4.29 2 
CD49d+ 0.001 1.78 1.27 to 2.51 
    
Age>65 years 0.0536 1.4 0.99 to 1.98 
    
Male 0.9232 0.98 0.70 to 1.38 
    
 
FISH categories were as reported by Dohner et al (ref. 7).  Weights were determined using the 
proportion of normalized hazard ratios rounded to the nearest whole integer.  Abbreviations: HR, 
hazard ratio; CI, confidence interval; WBC, white blood cell; UM, unmutated.  
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Figure Legends 
 
Figure 1.  Study design.  Training cohort: 478 cases included for univariable (UV) and 
multivariable (MV) analyses, scoring determination and risk category determination; 418 out of 
478 cases (with B2M data) were employed for comparison with CLL-IPI.  Validation cohorts 
included 1,401 Rai 0 cases.  The O-CLL cohort had 239/322 cases available for comparison to 
CLL-IPI.  In the remaining validation cohorts, all cases were available for comparison with CLL-
IPI. 
 
Figure 2.  Determination of the Rai 0 training cohort and CRO scoring.  Kaplan-Meier 
curves demonstrating % TFS for (A) a consecutive series of 1,201 cases of CLL referred to our 
center between 2006 and 2017 from which our training cohort was derived; stratified by Rai 
stage.  The training cohort of 478 Rai 0 cases organized according to (B) Dohner’s hierarchical 
model and (C) CRO score. 
 
Figure 3.  CRO score in validation cohorts.  Kaplan-Meier curves demonstrating % TFS in the 
validation cohorts.  Gemelli (A), Cardiff (B), Mayo (C), O-CLL (D), and composite validation 
(E) cohorts.  Blue: low-risk category, green: moderate-risk category, orange: high-risk category.      
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Supplemental Table 1. Clinical and laboratory features of CLL patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FISH categories were as reported by Dohner et al (Dohner H, N Engl J Med. 2000;343:1910-6). Abbreviations: WBC, white blood 
cell. 
 
 
 
  
Parameter n/total cases (%) 
 Training Gemelli Cardiff Mayo O-CLL  
Age ≥65, years 254/478 (53.1) 92/144 (63.9) 225/395 (60.0) 241/540 (44.6) 97/322 (30.1) 
WBC count >32x10
3
 cell/μL 141/478 (29.5) 5/144 (3.5) 110/395 (27.8) 92/540 (17.0) 29/322 (9.0) 
IGHV unmutated  94/478 (19.7) 35/144 (25.3) 83/395 (21.0) 178/540 (33.0) 97/322 (30.1) 
FISH category      
del17p 30/478 (6.3) 3/144 (2.1) 17/395 (4.3) 18/540 (3.3) 6/322 (1.9) 
del11q 36/478 (7.5) 6/144 (4.2) 32/395 (8.1) 38/540 (7.0) 18/322 (5.6) 
tri12 67/478 (14.0) 14/144 (9.7) 39/395 (9.9) 59/540 (10.9) 38/322 (11.8) 
Beta-2-microglobulin >3.5mg/L 36/418 (8.6) 21/144 (14.6) 92/395 (23.3) 70/540 (13.0) 1/239 (0.4)  
Follow-up median, months (95%CI) 62 (57-68)  91 (83-103) 94 (83-104) 77 (68-88) 89 (85-95) 
3 
 
Supplemental Table 2. Treatment free survival in CLL cases identified as high-risk according 
to the CRO model, stratified by score (N=309).  
 
CRO score Median, months 95% CI, months 
3 57.6  45.9-68.0  
4 44.0  36.0-64.0  
5 28.0  14.7-29.1  
Overall 51.6  42.6-60.0  
 
CLL cases were taken from the training and validation cohorts. Abbreviations: CI, confidence interval. 
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Supplemental Table 3: Subgroup univariable and reduced multivariable analysis involving 304/478 cases from 
the training cohort with available TP53 and NOTCH1 gene mutational status.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FISH categories were as reported by Dohner et al (ref. 7). Abbreviations: HR, hazard ratio; CI, confidence  
interval; WBC, white blood cell; UM, unmutated.  
 
Factor Univariable Analysis Reduced Multivariable Analysis 
P HR 95% CI P HR 95% CI 
WBC>32K cells/μL <0.0001 2.69 1.80-4.00 0.0009 2.02 1.33-3.06 
Dohner category             
del11q <0.0001 4.25 2.41-7.49 0.0234 1.95 1.09-3.47 
tri12 0.0001 2.75 1.67-4.53 0.0130 1.94 1.15-3.28 
UM IGHV <0.0001 3.98 2.64-5.98 <0.0001 2.57 1.64-4.04 
TP53 disrupted <0.0001 3.12 1.97-4.94 0.0086 2.01 1.94-3.39 
Del17p <0.0001 4.00 2.12-7.55 
   
    TP53 mutated <0.0001 3.33 2.07-5.38 
   
CD49d+ 0.0022 1.85 1.25-2.75 
   
NOTCH1 mutated 0.0003 2.25 1.45-3.48 
   
Age >65 years 0.0818 1.42 0.96-2.12 
   
Male  0.9251 1.02 0.69-1.51 
   
5 
 
 
Supplementary Figure 1.  Establishing a WBC count cutoff. Maximally selected log-rank statistic establishing a WBC 
count >32K cells/μL as our threshold.
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Supplementary Figure 2. Distribution plots demonstrating WBC count frequencies in the training cohort. Histogram of 
WBC count frequencies in (A) all 478 cases comprising the training cohort (B) cases with WBC count ≤32x103 and (C) 
cases with WBC count >32x103 cell/μL.
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21%
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17/220
46%
<0.5 Yes No
<2.5
Supplementary Figure 3. Risk group determination. A) Recursive partitioning demonstrating 2 cut-offs at <0.5 and  <2.5 
(within nodes, # of events/cases and % of total cases reported).  B) Risk group categorization into low (0) intermediate (1-
2) and high (3-5). 
Score  Risk Group
A B
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Supplementary Figure 4. Comparison to CLL-IPI. Kaplan-Meier curves demonstrating treatment free survival (%, Y-axis) in: (A) the training 
cohort (left panel, CRO score; right panel, CLL-IPI); (B) the Gemelli validation cohort (CLL-IPI; the corresponding CRO score is reported in 
Figure 3A); (C) the Cardiff cohort (CLL-IPI; the corresponding CRO score is reported in Figure 3B); (D) the Mayo cohort (CLL-IPI) the 
corresponding CRO score is reported in Figure 3C); (E) the O-CLL cohort (left panel, CRO score; right panel, CLL-IPI) .  Blue: low-risk category, 
green: moderate-risk category, orange: high-risk category, red: very high-risk category (CLL-IPI only); x axis: time in years.
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BA
Supplementary Figure 5. Overall treatment free survival in all cohorts. A) Kaplan-Meier curves demonstrating treatment 
free survival (%, Y-axis) for the training and 4 validation cohorts.  B) Statistical significance (P-value) comparing median 
treatment free survivals between all cohorts.
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Supplementary Figure 6. Comparison of CRO score and CLL-IPI in the composite cohort. Kaplan-Meier curves 
demonstrating treatment free survival (%, Y-axis) in the composite validation cohort determined by the CRO score (A) 
and CLL-IPI (B). Blue: low-risk category, green: moderate-risk category, orange: high-risk category, red: very high-risk 
category (CLL-IPI only).     
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Supplementary Figure 7. Treatment free survival in all high-risk cases determined according to the CRO score. Kaplan-
Meier curve demonstrating treatment free survival (%, Y-axis) stratified by CRO score in all high risk cases (N=309) taken 
from the training and validation cohorts. 
N=14
N=72
N=223
P=0.01
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Supplementary Figure 8. Application of the CRO score in Rai 1 patients.  Kaplan-Meier survival curves demonstrating 
treatment free survival (%, Y-axis) using the CRO score in Rai I patients applied to a consecutive series of Italian 
multicenter patients referred to our center for immunocytogenic analyses between 2006 and 2017. Blue: low-risk 
category, green: moderate-risk category, orange: high-risk category.
N=108
N=129
P<0.0001
P<0.0001
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c-index=0.67 
